基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Targeting Breast Cancer Stem Cells.
Targeting Breast Cancer Stem Cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
乳腺癌干细胞(BCSCs)在肿瘤发生和复发中的潜在作用已被认识数十年。由于其强大的自我更新和分化能力,BCSCs 是临床预后差和治疗反应低的主要原因。关于肿瘤干细胞起源,已提出几种假说,包括干细胞中的关键基因突变、体细胞去分化,以及由上皮-间质转化(EMT)和肿瘤微环境介导的细胞可塑性重塑。此外,肿瘤微环境,包括细胞成分和细胞因子,调节 BCSCs 的自我更新和治疗耐药性。靶向 BCSCs 的小分子、抗体和嵌合抗原受体(CAR)-T 细胞已被开发,其与传统疗法联合应用正在进行临床试验。在这篇综述中,我们聚焦于 BCSCs 的特征,强调调节 BCSCs 干性的主要因素和肿瘤环境,并讨论潜在的 BCSC 靶向治疗。
The potential roles of breast cancer stem cells (BCSCs) in tumor initiation and recurrence have been recognized for many decades. Due to their strong capacity for self-renewal and differentiation, BCSCs are the major reasons for poor clinical outcomes and low therapeutic response. Several hypotheses on the origin of cancer stem cells have been proposed, including critical gene mutations in stem cells, dedifferentiation of somatic cells, and cell plasticity remodeling by epithelial-mesenchymal transition (EMT) and the tumor microenvironment.
Moreover, the tumor microenvironment, including cellular components and cytokines, modulates the self-renewal and therapeutic resistance of BCSCs. Small molecules, antibodies, and chimeric antigen receptor (CAR)-T cells targeting BCSCs have been developed, and their applications in combination with conventional therapies are undergoing clinical trials. In this review, we focus on the features of BCSCs, emphasize the major factors and tumor environment that regulate the stemness of BCSCs, and discuss potential BCSC-targeting therapies.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。